// App-Quantinova.ai

3861 : Ruxolitinib inhibits STAT-3 activation in glioblastoma

Researchers

Presenter

  • Samuel Fehling

Principal Investigators

  • Braden McFarland

  • Etty Benveniste

Medical Centers

  • University of Alabama at Birmingham, Birmingham, AL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Brain cancer

  • Solid malignancies

Biomarkers

  • Interleukin 6

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved